Overview

Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses

Status:
NOT_YET_RECRUITING

Trial end date:
2027-09-30

Target enrollment:

Participant gender:

Summary

The main objective of this study is to evaluate at 96 weeks the safety with respect to hepatitis B control of 2 treatment reduction strategies for patients with previously controlled HIV-HBV co-infection on continuous triple therapy

Phase:

PHASE2

Details

Lead Sponsor:

ANRS, Emerging Infectious Diseases

Treatments:

dolutegravir
Racivir